Janney Montgomery Scott began coverage on shares of Nightstar Therapeutics (NASDAQ:NITE) in a research report sent to investors on Wednesday, MarketBeat reports. The firm issued a buy rating and a $34.00 price target on the stock.

A number of other equities research analysts have also recently commented on NITE. Mizuho reaffirmed a buy rating and set a $20.00 price objective on shares of Nightstar Therapeutics in a research note on Friday, April 27th. ValuEngine raised Nightstar Therapeutics from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Zacks Investment Research cut Nightstar Therapeutics from a hold rating to a sell rating in a research note on Wednesday, June 6th. Chardan Capital reaffirmed a buy rating and set a $40.00 price objective on shares of Nightstar Therapeutics in a research note on Wednesday, June 6th. Finally, UBS Group cut Nightstar Therapeutics from an outperform rating to a market perform rating in a research note on Wednesday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $29.29.

NITE stock opened at $19.89 on Wednesday. The firm has a market cap of $556.10 million and a PE ratio of -12.21. Nightstar Therapeutics has a twelve month low of $10.01 and a twelve month high of $24.93.

Nightstar Therapeutics (NASDAQ:NITE) last released its earnings results on Monday, August 13th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.12. research analysts forecast that Nightstar Therapeutics will post -1.63 EPS for the current year.

Several institutional investors have recently made changes to their positions in NITE. Woodford Investment Management Ltd acquired a new stake in shares of Nightstar Therapeutics during the second quarter worth $5,024,000. Millennium Management LLC acquired a new position in Nightstar Therapeutics in the first quarter valued at about $507,000. Redmile Group LLC grew its stake in Nightstar Therapeutics by 0.9% in the second quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock valued at $28,567,000 after acquiring an additional 16,500 shares during the period. Stanley Laman Group Ltd. acquired a new position in Nightstar Therapeutics in the second quarter valued at about $195,000. Finally, Bank of America Corp DE acquired a new position in Nightstar Therapeutics in the second quarter valued at about $132,000. 30.40% of the stock is owned by institutional investors and hedge funds.

Nightstar Therapeutics Company Profile

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Read More: Are Wall Street analysts’ stock ratings worth following?

Analyst Recommendations for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.